Original Article
  

Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial

Abstract

Allergic rhinitis is a common childhood disease. Although various drugs have been used to treat allergic rhinitis, including nasal corticosteroids, antileukotrienes, and antihistamines, there is still controversy about the optimal dose and the best combination with the highest efficacy. Higher doses of antihistamines are recommended for better control of urticaria, but there is insufficient evidence regarding the efficacy of increased doses of antihistamines in allergic rhinitis. The aim of the study was to evaluate the effectiveness of different drug combinations in the treatment of children with allergic rhinitis.
Sixty-four children with persistent moderate to severe allergic rhinitis were enrolled and randomly divided into 4 groups. All children received mometasone furoate nasal spray once daily. In addition to mometasone, each group received one of the following drugs or drug combinations: daily desloratadine, twice daily desloratadine, montelukast, or a combination of desloratadine and montelukast. The severity of symptoms before and after the intervention was evaluated based on the total nasal symptoms score, including sneezing, nasal congestion, nasal itching, and rhinorrhea.
Sixty patients completed the study. The reduction of nasal congestion score and total nasal symptoms score in the groups receiving desloratadine twice a day and desloratadine plus montelukast was superior to the daily desloratadine group and daily montelukast groups.
According to this work, the treatment of allergic rhinitis with mometasone nasal spray with desloratadine twice a day or with the combination of desloratadine and montelukast was more effective than other treatment regimens.

1. Wise SK, Damask C, Greenhawt M, Oppenheimer J, Roland LT, Shaker MS, et al. A Synopsis of Guidance for Allergic Rhinitis Diagnosis and Management From ICAR 2023. J Allergy Clin Immunol Pract. 2023;11(3):773-96.
2. Wise SK, Damask C, Roland LT, Ebert C, Levy JM, Lin S, et al. International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol. 2023;13(4):293-859.
3. Diniz AF, Ribeiro JA, Lira GV, Sarinho ES. Allergic Rhinitis in Preschoolers: A Systematic Review of Diagnostics. Am J Rhinol Allergy. 2023;37(3):360-68.
4. Pang K, Li G, Li M, Zhang L, Fu Q, Liu K, et al. Prevalence and Risk Factors for Allergic Rhinitis in China: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2022;2022(25):7165627.
5. Sharma K, Akre S, Chakole S, Wanjari MB. Allergic Rhinitis and Treatment Modalities: A Review of Literature. Cureus. 2022;14(8):e28501.
6. Ankermann T, Brehler R. Allergic asthma: An indication for allergen immunotherapy. Allergol Select. 2023;7:33-8.
7. Lin CF, Lin YT, Liao CK, Yeh TH. Recent Updates of Immunotherapy for Allergic Rhinitis in Children. Curr Otorhinolaryngol Rep. 2023;11(1):37-43
8. Indolfi C, Dinardo G, Umano GR, Klain A, Contieri M, Decimo A, et al. Mometasone furoate nasal spray in Italian children with seasonal allergic rhinitis: a comprehensive assessment. Allergol Immunopathol (Madr). 2022;50(5):61-7.
9. Marrs T, Anagnostou K, Fitzsimons R, Fox AT. Optimising treatment of allergic rhinitis in children. Practitioner. 2013;257(1762):13-8,2.
10. Ranasinghe C, Prashar J. Is montelukast monotherapy effective for the management of allergic rhinitis in children? Arch Dis Child. 2022;107(2):197-201.
11. Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Walter Canonica G, et al. Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95.
12. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 Mar;77(3):734-66.
13. Dai W, Zhen N, Qin X, Cao J. Effect of momethasone furoate combined with loratadine and montelukast sodium on inflammatory factors and pulmonary function in children with allergic rhinitis. Am J Transl Res. 2022;14(10):7199-207.
14. Jia MH, Chen XY, Zhang Y, Liao ZS. [Effect of nasal glucocorticoid combined with loratadine or montelukast on allergic rhinitis]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;31(5):369-373.
15. Anolik R. Mometasone Furoate Nasal Spray with Loratadine Study Group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(3):264-71.
16. Yang C, Shangguan C, Cai C, Xu J, Qian X. LncRNA HCP5 Participates in the Tregs Functions in Allergic Rhinitis and Drives Airway Mucosal Inflammatory Response in the Nasal Epithelial Cells. Inflammation. 2022;45(3):1281-97.
17. Chen Q, Shao L, Li Y, Dai M, Liu H, Xiang N, et al. Tanshinone IIA alleviates ovalbumin-induced allergic rhinitis symptoms by inhibiting Th2 cytokine production and mast cell histamine release in mice. Pharm Biol. 2022;60(1):326-33.
18. Haccuria A, Van Muylem A, Malinovschi A, Doan V, Michils A. Small airways dysfunction: the link between allergic rhinitis and allergic asthma. Eur Respir J. 2018;51(2):1701749.
Files
IssueVol 23 No 4 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijaai.v23i4.16211
Keywords
Allergic rhinitis Children Desloratadine Mometasone furoate Montelukast
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ghanbari N, Eftekhari K, Samadzadeh-Mamaghani M, Sedighiyan M, Diaz D, Shafiei A. Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial. Iran J Allergy Asthma Immunol. 2024;23(4):366-373.